Statement to the 21st meeting of the WHO Expert Committee on Selection and Use of Essential Medicines

Presented by Dr. Marg Ewen on 27 March 2017 | Click here to download the full statement.

Comment from Health Action International to Expert Committee on the application to include long-acting analogue insulins in the WHO Model List of Essential Medicines

Submission to the Expert Committee from HAI

Insulin discounts lower price burden for Americans, but insulin still not affordable worldwide

AMSTERDAM— Researchers conducting a global study into the barriers to insulin access call on Eli Lilly, Novo Nordisk and Sanofi to lower prices for all types of insulin worldwide and for greater transparency of actual prices paid for insulin. Read more 

ACCISS Study Reveals Numerous Barriers Hindering Access to Insulin for Millions in Need

GENEVA—A number of barriers are impeding access to insulin around the world, according to new research published today by Health Action International, Geneva University Hospitals/University of Geneva and Boston University School of Public Health. Read more 

Listen: ACCISS Study Investigator, David Beran, Speaks to The Lancet D&E About Insulin Access

Coinciding with the release of the ACCISS Study’s new Review, ‘Constraints and Challenges in Access to Insulin: A Global Perspective‘, in The Lancet Diabetes & Endocrinology, co-author David Beran spoke with the journal about key issues affecting access to insulin. Read more

Innovative Global Study Launched to Improve Access to Insulin

AMSTERDAM—Health Action International (HAI) has launched an innovative global study, called Addressing the Challenges and Constraints of Insulin Sources and Supply (ACCISS), to identify the causes of poor availability and high insulin prices and develop policies and interventions to improve access to this life-saving medicine, particularly in the world’s most under-served regions. Read more

START TYPING AND PRESS ENTER TO SEARCH